Important Safety Information | Prescribing Information
*As demonstrated in a phase 3 open-label, randomized, controlled, multicenter clinical trial (N=164) in which patients with herpetic keratitis received either ZIRGAN or acyclovir ophthalmic ointment 3%, administered 5 times daily until healing of ulcer and then 3 times daily for 1 week. Clinical resolution (healed ulcers) at day 7 was achieved in 77% (55/71) of patients treated with ZIRGAN versus 72% (48/67) treated with acyclovir (difference, 5.8%; 95% CI, -9.6%-18.3%). ZIRGAN was noninferior to acyclovir in patients with dendritic ulcers.
See below for Indication and Important Safety Information.
ZIRGAN (ganciclovir ophthalmic gel) 0.15% is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).
IMPORTANT SAFETY INFORMATION
ZIRGAN is indicated for topical ophthalmic use only.
Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN.
Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
Safety and efficacy in pediatric patients below the age of 2 years have not been established.
Click here for Prescribing Information about ZIRGAN.
References: 1. Foster CS. Ganciclovir gel—a new topical treatment for herpetic keratitis. US Ophthalmic Rev. 2008;3(1):52-56. 2. ZIRGAN Prescribing Information, April 2014. 3. Croxtall JD. Ganciclovir ophthalmic gel 0.15% in acute herpetic keratitis (dendritic ulcers). Drugs. 2011;71(5):603-610.
Zirgan is a trademark of Laboratoires Théa Corporation used under license.